Amp Volatility Score
Catalyst Info & Data Links
TITLE: HTX-019-202 - CINVANTI® (aprepitant) Treatment in COVID-19
ClinicalTrial.gov (NCT04470622): Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION / RATIONALE
Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors. Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis.
Updated by HC
#HRTX, #HTX-019-202, #CINVANTI, #aprepitant, #GUARDS-1, #COVID, #COVID-19, #coronavirus
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post